OpenScience.ink

3 weeks ago • Cardiology

Semaglutide Use and Discussion in Obese Patients with Heart Failure and Normal Heart PumpingSemaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.

📖 Top 50% JournalArticle

3 weeks ago • Obesity facts

Weight changes from GLP-1RA treatment in patients with PCSK1 gene mutations – two case reportsGLP-1RA based treatment in patients with a PCSK1 mutation has profound effects on body weight - two case reports.

🎖️ Top 10% JournalCase Reports

3 weeks ago • Annals of clinical and translational neurology

Effects of Glucagon-Like Peptide-1 Receptor Activators in Multiple Sclerosis: A Focused ReviewGlucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.

🎖️ Top 10% JournalArticle

3 weeks ago • Clinics in dermatology

Metabolism and Skin Health: New Diabetes-Related Drugs as Immune and Metabolic Treatments for Obesity-Linked Skin ProblemsThe Metabolic-Dermatologic Axis: GLP-1/GIP Agonists as Emerging Immunometabolic Therapies for Obesity-Associated Skin Disease.

📖 Top 50% JournalArticle

3 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

Treating Sleep Apnea in Obesity: Using Airway Pressure, Blood Sugar Hormone Therapy, or Both?Rethinking Obstructive Sleep Apnea Care in Obesity: Continuous Positive Airway Pressure, Incretin-Based Therapy, or Both?

Article

3 weeks ago • Clinical nutrition ESPEN

Side Effects of Semaglutide Reported to the U.S. FDACharacterizing the adverse event profile of semaglutide: A comprehensive U.S. food and drug administration adverse event reporting system-based pharmacovigilance study.

📖 Top 30% JournalArticle

3 weeks ago • Hormone research in paediatrics

Keeping Weight Stable After Stopping Semaglutide in a Teen with Weight Gain from Antipsychotic Medication: A Case ReportWeight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report.

📖 Top 20% JournalCase Reports

3 weeks ago • The European respiratory journal

GLP-1 Treatments for Lung DiseasesGLP-1-based therapies in lung diseases.

🥈 Top 2% JournalArticle

3 weeks ago • Obesity pillars

Challenges and high costs of starting glucagon-like peptide-1 therapy in young adultsHope, hype, and high costs: Navigating glucagon-like Peptide-1 based therapy initiation among young adults.

📖 Top 20% JournalArticle

3 weeks ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

Using Combined Glucagon and Incretin Signals to Treat Obesity and Fatty Liver DiseaseThe Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.

Article

3 weeks ago • International medical case reports journal

Severe Diabetic Ketoacidosis with Normal Blood Sugar After Poor Eating Linked to Semaglutide, Despite Stopping Empagliflozin: A Case ReportSevere Euglycemic Diabetic Ketoacidosis After Semaglutide-Associated Poor Intake Despite Empagliflozin Discontinuation: A Case Report.

Case Reports

3 weeks ago • Kidney research and clinical practice

Combined empagliflozin and liraglutide treatment may protect the pancreas and kidneys from tacrolimus damage by reducing oxidative stressCombined empagliflozin and liraglutide therapy protects against tacrolimus-induced pancreatic and renal injury associated with oxidative stress reduction.

📖 Top 20% JournalArticle

3 weeks ago • Frontiers in endocrinology

🎖️ Top 10% JournalArticle

3 weeks ago • bioRxiv : the preprint server for biology

Long-term semaglutide treatment reduces cue-driven cocaine relapse and repetitive cocaine behaviors in male and female ratsChronic semaglutide treatment attenuates cue-induced reinstatement of cocaine-seeking and cocaine-induced stereotypy in male and female rats.

Preprint

3 weeks ago • Biology methods & protocols

Cardiometabolic benefits and side effects of low-dose semaglutide versus tirzepatideComparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide.

📖 Top 30% JournalArticle

3 weeks ago • American journal of clinical pathology

Tirzepatide may cause rare but serious air pockets in the intestinesTirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect.

📖 Top 30% JournalCase Reports

3 weeks ago • Journal of the Endocrine Society

Glucagon-like peptide 1 receptor drugs and their possible link to sudden optic nerve damageCurrent review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy.

📖 Top 20% JournalArticle

3 weeks ago • Haemophilia : the official journal of the World Federation of Hemophilia

Glucagon-Like Peptide-1 Signaling and Its Role in Joint Bleeding, Inflammation, and Cartilage Damage in HemophiliaImplications of Glucagon-Like Peptide-1 Signaling for Hemophilic Arthropathy, Joint Inflammation, and Cartilage Degeneration: A Narrative Review.

📖 Top 20% JournalArticle

3 weeks ago • Clinics in dermatology

Changes in Facial Appearance and Aging Linked to Ozempic Use"Ozempic Face" and Facial Aging.

📖 Top 50% JournalArticle

3 weeks ago • Biochemical pharmacology

A combined GLP-1 and apelin receptor activator may protect brain cells in a mouse model of Parkinson’s diseaseA GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease.

Article

3 weeks ago • HSS journal : the musculoskeletal journal of Hospital for Special Surgery

Use of GLP-1 Receptor Agonists Linked to Lower Early Hip Replacement Revision Risk Compared to Weight-Loss SurgeryGLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study.

📖 Top 30% JournalArticle

3 weeks ago • The Journal of clinical endocrinology and metabolism

Incretin treatment before pregnancy may lower pregnancy problems and heart-related risks in polycystic ovary syndromePreconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome.

🥉 Top 5% JournalArticle

3 weeks ago • JACC. Advances

Heart Risk in Heart Attack Patients with Overweight or Obesity Eligible for SELECT Treatment in Western DenmarkCardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.

🎖️ Top 10% JournalArticle

3 weeks ago • Frontiers in pharmacology

Comparing SGLT2 inhibitors, semaglutide, and finerenone for diabetic kidney disease using network analysisSGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.

📖 Top 20% JournalArticle

3 weeks ago • microPublication biology

Semaglutide lowers smell-driven movement and reproduction in roundwormsSemaglutide Reduces Odorant-Driven Chemotaxis and Reproductive Output in Caenorhabditis elegans.

Article

3 weeks ago • Canadian journal of physiology and pharmacology

How Incretin Hormones Work: New Advances from Research to TreatmentIncretins in Action: Unlocking New Frontiers from Bench to Bedside.

📖 Top 50% JournalIntroductory Journal Article

3 weeks ago • Journal of diabetes

Use and Costs of Diabetes Drugs That Activate GLP-1 from 2008 to 2023Diabetes Medication Market: Costs and Utilization of Glucagon-Like Peptide 1 (GLP-1) Prescriptions From 2008 to 2023.

📖 Top 20% JournalLetter

3 weeks ago • Frontiers in endocrinology

The full treatment journey of incretin and multi-receptor drugs beyond their effectivenessBeyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.

🎖️ Top 10% JournalArticle

3 weeks ago • Microbiological research

How gut bacteria and natural GLP-1 interact in chronic pancreatitis and possible repair processesThe gut-pancreas axis in chronic pancreatitis: Microbiota-endogenous GLP-1 interactions and candidate repair pathways.

🎖️ Top 10% JournalArticle

3 weeks ago • ACS omega

Finding New Peptides That May Block DPP-IV Using Computer Models and Early Lab TestsDiscovery of Novel Peptides as DPP-IV Inhibitors: In Silico Screening, Molecular Dynamics Simulations, and Preliminary In Vitro Evaluation.

📖 Top 30% JournalArticle

← prevpage 13 of 16next →

Latest GLP-1 Therapies Research Papers